Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma

The objective of this study was to evaluate the efficacy and safety of dovitinib in patients with adenoid cystic carcinoma (ACC).

[1]  Y. Bang,et al.  A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma , 2014, BMC Cancer.

[2]  A. Ravaud,et al.  Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer , 2014, Clinical Cancer Research.

[3]  J. Lee,et al.  Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib , 2013, British Journal of Cancer.

[4]  J. Soria,et al.  Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma , 2013, Clinical Cancer Research.

[5]  Xiaofeng Wang,et al.  Population Pharmacokinetic/Pharmacodynamic Modeling to Assist Dosing Schedule Selection for Dovitinib , 2013, Journal of clinical pharmacology.

[6]  L. Siu,et al.  A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J. Kirkwood,et al.  Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma , 2011, Clinical Cancer Research.

[8]  A. Ho,et al.  Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. , 2011, The Lancet. Oncology.

[9]  L. Mariani,et al.  Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. , 2009, Oral oncology.

[10]  I. Judson,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[11]  Xiangbing Wu,et al.  [Effects of basic fibroblast growth factor on the proliferation of human salivary adenoid cystic carcinoma cell line ACC-2 and extracellular signal-regulated kinase, Cyclin D1, p2waf/cip1 signaling pathway]. , 2008, Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology.

[12]  D. Hayes,et al.  Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. A. van de Wiel,et al.  DNA Copy Number Gains at Loci of Growth Factors and Their Receptors in Salivary Gland Adenoid Cystic Carcinoma , 2007, Clinical Cancer Research.

[14]  M. Levitt,et al.  A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. , 2007, Oral oncology.

[15]  Yan Tang,et al.  CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia , 2005, Clinical Cancer Research.

[16]  Sang Hoon Lee,et al.  In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models , 2005, Clinical Cancer Research.

[17]  E. Lamont,et al.  Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Roh,et al.  Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. , 2003, Archives of otolaryngology--head & neck surgery.

[19]  G. Snow,et al.  Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow‐up , 2002, Head & neck.

[20]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[21]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[22]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[23]  H. Goepfert,et al.  Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. , 1999, Archives of otolaryngology--head & neck surgery.

[24]  M. Kan,et al.  IMMUNOHISTOCHEMICAL STUDY OF OVEREXPRESSION OF FIBROBLAST GROWTH FACTOR‐1 (FGF‐1), FGF‐2, AND FGF RECEPTOR‐1 IN HUMAN MALIGNANT SALIVARY GLAND TUMOURS , 1996, The Journal of pathology.

[25]  S. Rodenhuis,et al.  Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  R. Spiro.  Salivary neoplasms: overview of a 35-year experience with 2,807 patients. , 1986, Head & neck surgery.